Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing- Off.
Parkinson's Disease
About this trial
This is an interventional treatment trial for Parkinson's Disease
Eligibility Criteria
Inclusion Criteria: patients suffering from idiopathic Parkinson's Disease (PD) with wearing-off phenomenon OFF-time per day >= 60 min after the first ON-period in the morning 3-5 daily dosages of standard levodopa/DDC inhibitor stable antiparkinsonian treatment 3 weeks prior to the randomisation Exclusion Criteria: symptomatic parkinsonism concomitant treatment with non-selective MAO inhibitors or a selective MAO-A inhibitor while treated with a MAO-B inhibitor already concomitant treatment with one of the following catechol-structured drugs: rimiterol, isoprenaline, adrenaline, noradrenaline, dopamine, dobutamine or apomorphine concomitant treatment with alpha-methyldopa, reserpine, typical or atypical neuroleptics, neuroleptic antiemetics (such as metoclopramide) or other drugs with antidopaminergic action treatment with COMT-inhibitors 4 weeks prior to the randomisation treatment with dopamine agonists 4 weeks prior to the randomisation known hypersensitivity to ergot derivatives and entacapone dementia (MMSE <= 24) depression (Beck Scale >= 17)
Sites / Locations
- Orion Pharma GmbH